Sotera Health president Rutz sells $2.83m in common stock

Michael P. Rutz, President of Sterigenics, a subsidiary of Sotera Health Co (NYSE:SHC), disposed of 150,000 shares of the company’s common stock on August 7, 2026. The transactions totaled approximately $2,825,250. The sale comes as the stock trades near its 52-week high of $19.85, with shares currently at $18.89. The company carries a market cap of $5.43 billion and trades at a P/E ratio of 33.34.

The shares were sold at varying prices between $18.75 and $18.9050 per share, with an average weighted price of $18.835. Following this transaction, Mr. Rutz directly beneficially owns 334,279 shares of Sotera Health common stock. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive Pro Research Reports, available for SHC and 1,400+ US equities.

In other recent news, Sotera Health reported impressive second-quarter earnings results, surpassing Wall Street expectations. The company announced adjusted earnings of $0.26 per share, exceeding the anticipated $0.24, alongside revenue of $321.37 million, which also beat the forecast of $309.64 million. This performance reflects a 9.2% increase in revenue compared to the same period last year, with adjusted EBITDA climbing by 10% and margins showing improvement. Management has consequently raised the full-year 2026 outlook for revenue, adjusted EBITDA, adjusted EPS, and interest expense. All three business units—Sterigenics, Nordion, and Nelson Labs—reported growth, contributing to this positive financial outcome. Additionally, Sotera Health reached its long-term leverage target and concluded the quarter with approximately $950 million in liquidity. In a separate development, the company announced the resignation of James C. Neary from its Board of Directors. Sotera Health clarified that Neary’s departure was not due to any disagreements regarding company operations or policies.